Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 4
Submit an article Journal homepage
4
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Cardiovascular and Renal Patent Update: Recent advances in potassium channel openers: patent activity June 1992 to August 1993

John A Butera Wyeth-Ayerst Research, Divisions of Cardiovascular/Diabetes Chemistry, CN 8000, Princeton, New Jersey, 08543-8000, USA
&
Richard M Soll Wyeth-Ayerst Research, Divisions of Cardiovascular/Diabetes Chemistry, CN 8000, Princeton, New Jersey, 08543-8000, USA
Pages 395-408 | Published online: 03 Mar 2008

References to Primarv Literaturess

  • STINSON SC: New drugs under development for diabe-tes. Chem. Eng. News, September 30, (1991):35–59.
  • CIMINI MG, GIBSON, JK: Recent advances in anti-ar-rhythmic therapy: potassium channel antagonists. In: Annual Reports in Medicinal Chemistry Vol. 27 (1992). BRISTOL JA (Ed.), Academic Press Inc, San Diego.
  • ANDERSSON KE: Clinical pharmacology of potassium channel openers. Pharmacology and Toxicology (1992) 70:244–254.
  • BUCKLE DR: Prospects for potassium channel activators In the treatment of airways obstruction. Pulmonary Pharmacology (1993) 6:161–169.
  • BUCKLE DR, ARCH JRS: Potassium channel activators and airways disease. DN&P (1993) 6:279–288.
  • A comprehensive assessment of the potential use of KCO s for airways disease.
  • NURSE DE, RESTORICK JM, MUNDY AR: The effect ofcromakalim on the normal and hyperreflexic human detrusor muscle. Br. J. Urol. (1991) 68:27–31.
  • FUFII K, FOSTER CD, BRADING AF, PAREKH AB: Potas-sium channel blockers and the effects of cromakalim on the smooth muscle of the guinea-pig bladder. Br. J. Pharmacol. (1990) 99:779–785.
  • ESCANDE D, CAVERO I: 1C+ channel openets and 'natural' cardioprotection. TiPS (1992) 13:269-27. Provides rationale for use of KCOs as cardioprotective agents.
  • ARONSON JK: Potassium channels in nervous tissue. Biochemical Pharmacology (1992) 43:11–14.
  • WESTON All, EDWARDS G: Recent progress in potassium channel opener pharmacology. Biochemical Pharmacol-ogy (1992) 43:47–54.
  • LONGMAN SD, HAMILTON TC: Potassium channel acti-vator drugs; mechanism of action, pharmacological properties, and therapeutic potential. Medicinal Re-search Reviews (1992) 12:73–148.
  • GOPALAKRISHNAN M, JANIS RA, TRIGGLE DJ: ATP-sensi the K.-channels: pharmacological properties, regula-tion, and therapeutic potential. Drug Dev. Res. (1993) 28:95-127. Thorough review of KCOs.
  • ATWAL KS: Modulation of potassium channels by or-ganic molecules. Medicinal Research Reviews (1992) 12:569-591. Comprehensive review emphasizing KATp and KCa channels.
  • WESTON AH, EDWARDS G: The pharmacolgy of ATP-sen-sitive potassium channels. An flu. Rev. Pharmacol. Toxicol.(1993) 33:597-637. Extensive review of ATP-sensitive K-channels and their modulators.
  • NELSON MT: Ca2+ activated potassium channels and atp-sensitive potassium channels as modulators of vascular tone. Trends in Cardiovascular Medicine (1993) 3:54–60.
  • QUAST U: Potassium channel openers: pharmacologi-cal and clinical aspects. Fundam. Clin. Pharmacol. (1992) 6:279–293.
  • MCPHERSON GA: Current trends in the study of potas- sium channel openers. Gen. Pharmacol. (1993) 24:275–281.
  • EDWARDS G, WESTON AH: Structure-activity relation-ships of K+ channel openers. TiPS (1990):417–422.
  • McCAULLY RJ: Variations on the Benzopyran Nudeus. Current Drugs. Potassium Channel Modulators. (1991) KCM B5–B19.
  • EVANS JM, LONGMAN SD: Potassium channel activators.In: Annual Reports in Medicinal ChemistryVol. 26 (1991): 73–82. BRISTOL JA (Ed.), Academic Press Inc, San Diego.
  • CHAPMAN RF: Antihypertensive thioformamides: a chemist's view. Current Drugs: Potassium Channel Modu-lators (1991): KCM B63–B69.
  • CHAPMAN RF: Antihypertensive thioformatnides: achemist's view (part 2). Current Drugs: Potassium Channel Modulators (1993) KCM C1–C19.
  • ALMANSA C, GOMEZ L A, CAVALCANTI F L, RODRIGUEZ R, CARCELLER E, BARTROLF J, GARCIA-RAFANELL J, FORN J: 2,2- Dialkylnaphthalen-1 -ones as new potassium channel activators. J. Med. Chem (1993) 36:2121–2133.
  • CASIS 0, PEREZ-VIZCAINO F, RODRIGUEZ R, GOMEZ LA, RAFANELL JG, TAMARGO J: The effects of the novel potassium channel opener ur-8225 on isolated rat vas-cular smooth muscle. Br. J. Pharmacol. (1993) 108 (suppl):182P.
  • MASUDA N, UCHIDA W, ARAI Y, TAGUCHI T, TSUZUKI R,INAGAKI 0, TAICENAKA T: Pharmacological profiles of YM099, a new le channel opener. Japan. J. Pharmacol. (1993) 61 (SuppL I):P–113.
  • UCHIDA W, MASUDA N, TAGUCHI T, INAGAKI 0, TSUZUKIR, TAKENAKA T: Cardiovascular effects of YM099, a novel k channel opener. Japan. j Pharmacol. (1993) 61 (SuppL 1):P–114.
  • AWANE Y, KUSUMOTO K, HASHIGUCHI S, SHIRAISHI M,WATANABE T: Pharmacological property of a new po-tassium channel opener, TCV-295 in vitro. Japan. J. Pharmacol. (1993) 61 (SuppL I):P–154.
  • KUSUMOTO K, FUJIWARA S, KITAYOSHI T, AWANE Y, WATANABE T: Antihypertensive and hemodynamic ef-fects of a new potassium channel opener, TCV-295, in rats and dogs. Japan. J. Pharmacol. (1993) 61 (SuppL 0:P–115.
  • BAZIL MK, UKROPEC JA AND WILLIAMS PD: Haemody-namic and electrocardiographic (ECG) effects of CL-188,294, a potassium channel opener, in consdous dogs. American Society for Pharmacology and Experimental Therapeutics (1993): Abs 266.
  • GAD WOOD RC, KAMDAR BV, CIPKUS DUBRAY LA, WOLFEML, SMITH MP, WAIT W, MIZAK SA, GROPPI VE: Synthesis and biological activity of spirocyclic potassium channel openers. J. Med. Chem. (1993) 36:1480–1487.
  • MATSUKURA M, DAIKU, Y, UEDA K, TANAKA S, IGARASHIT, MINAMI N: Synthesis and antiarrhythmic activity of 2,2-dialkyl- l'-(N-substituted aminoalkyl)-spiro-[chro-man-4,4'-imidazolidine]-2',5'-diones. Chem Pharm. Bull. (1992) 40:1823–1827.
  • Current Drugs, KC Modulators Update, September 1993: All.
  • ATWAL KS, MORELAND S, MCCULLOUGH JR, AHMED SZ, NORMANDIN DE: Benzopyranyl-cyanoguankline potas-sium channel openers. Bioorg. Med. Chem. (1992) 2:87–90.
  • TOOMBS CF, NORMAN NR, GROPPI VE, LEE KS, GAD-WOOD RC, SHEBUSKI RJ: Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.J. Pharmacol. Exp. Ther. (1992) 263:1261-1268. Paper demonstrates the separation of anti-ischaemic effects from cardiovascular liabilities.
  • GROVER GJ, SARGENT CA,. MCCULLOUGH JR AND ATWALKS: In viiroanti-ischaemic profile of a novel cardiose-lective Kgrp opener, BMS 180448. The Pharmacologist (1993) 35:Abs 267.
  • Current Drugs, KC Modulators Update, August 1992: KAK1–3.
  • JACOBSEN EN, ZHANG W, MUCI AR, ECKER JR, DENG L:Highly enantioselective epoxidation catalysts derived from 1,2-diarainocyclohexane. J. Am. Chem. Soc. (1991) 113:7063-7064. TAKEMOTO T, EDA E, HIHARA M, OKADA H, SAKASHITA M, EIRAKU M, FUKAYA C, MATZUNO S, GODA M, EBISU H, NAKAMURA N, YAMANOUCHI K, YOKOYAMA KA: Potent K+ channel opener: chemistry and evaluation of antihypertensive activity of diaminopyridine deriva-tives. 204th ACS Meeting, Washinton DC, US (1992): MEDI51.
  • GOHDA M, EBISU H, MATZNO S, OKITA M, KIDO H, KUBO Y, UCHIDA T, NAKAMURA N, WATANABE M: Antihyper-tensive and serum lipids lowering effects of AL0671, a novel potassium channel opener. Jpn. j Pharmacol. (1993) 61 (Suppl DP–112.
  • Current Drugs, KC Modulators Update, June 1993: A8–A9.
  • Current Drugs, KC Modulators Update, September 1993: KIR 1–7.
  • ISHIBASHI T, HAMAGUCHI M, IMAI S: Vasodllating prop-erties of km-2391: structural basis of a new pyridine-type potassium channel opener with a nitrate moiety. Naunyn-Schmied Arch. Pharmacol. (1992) 346:94–101.
  • OKADA Y, YANAGISAWA T, TAIRA N: An analysis of the nitrate-like and K-channel opening actions of KRN-2391 in canine coronary arterial smooth muscle. Br. J. Pharmacol. (1991) 104:829–838.
  • OKADA Y, YAMAGISHI T, YANAGISAWA T, TAIRA N: Ananalysis of the nitrate-like and K-channel opening actions of KRN-2391 in canine coronary arterial smooth muscle. JpnJ. Pharmacol. (1992) 58 (SuppL 2):333P.
  • KASAI H, EUKATA Y, HARADA K, FUKUSHIMA H, OGAWA N: Dissimilarity in the mechanisms of action of ICRN2391, nicorandil and cromakalim in canine renal artery. J. Pharm. Pharmacol. (1993) 45:222–224.
  • OGAWA N, FUKATA Y, KANETA S, JINNO Y, MIWA A, FUKUSHIMA H: Mechanism of action of KRN2391, a novel vasodilator, in canine mesenteric artery. Jpn. J. Pharmacol. (1993) 61:303–309.
  • OGAWA N, NISHIKORI K: Profile of ICRN2391, a novel vasodilator with properties of a nitrate potassium chan-nel opener hybrid. Jpn. J. Pharmacol. (1992) 59 (SuppL 0:38P.
  • GLEN AT, HUGHES LR, MORRIS JJ, TAYLOR PJ: Structure-activity relationships among non-steroldal antiandro-gens. In: Proc. of the 3rd SCI-RSC Med. Chem. Symp. (1986) LAMBERT RW (Ed.): 345–361.
  • JAIN SM, KHAJURIA RK, DHAR ILL, SINGH S, BANI S, PAHWA, GS, SINGH GB: Synthesis and pharmacological screening of 1,8-dioxo-9-(substituted phenyl)-1,2,3,4,5,6,7,8,9,10- decahydroacridines. Indian Journal of Chemistry (1991) 30B:1037–1040.
  • 1CLOCKNER U, TRIESCHMANN U, ISENBERG G: Pharma-cological modulation of calcium and potassium chan-nels in isolated vascular smooth muscle cells. Arzneim.-Forsch . Drug Res. (1989) 39:120–126.
  • CAVERO I, ALOUP J-C., MONDOT S, LEMONNIER DE GOU-VILLE A, MESTRE M: Cardiovascular pharmacology of the carbothioamide IC channel opener RP-49356 and its active enantiomer, aprikalim, RP-52891. Current Drugs, Potassium Channel Modulators (1991) KCM-B70–B81.
  • Current Drugs, Potassium Channel Modulators Update, Au-gust 1993:EIS 1–3.
  • DE SOUZA NJ, DOHADWALLA AN, REDEN J: Forskolin: a labdane diterpinoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adeny-late cyclase activating properties. Med. Res. Rev. (1983) 3:201–219.
  • KHANDELWAL Y, RAJESHWARI K, RAJAGOPALAN R, SWAMY L, DOHADWALLA AN, DE SOUZA NJ, RUPP RH: Cardiovascular effects of new water soluble derivatives of forskolin J. Med. Chem. (1988) 31:1872–1879.
  • SEAMON KB: FORSKOLIN AND ADENYLATE CYCLASE: New opportunities in drug design. In: Annual Reports in Medicinal Chemistry Vol. 19 (1984). BAILEY DM (Ed.), Academic Press, Inc. San Diego.
  • LINZ W, ENGLERT H, KAISER J, KLAUS E, ME'TZGER H,WIRTH K, SCHOELKENS BA: Evidence for an involvment of potassium channels in the action of forskolin and 1,9-dideoxyforskolin. Pbarm. Pharmacol. Lett. (1992) 1:99–102.
  • BOWRING NE, BUCKLE DR, TAYLOR JF, ARCH JRS: BRL55834: A novel potassium channel activator that is more selective for the airways in the guinea-pig and rat compared with BRL 38227. Br. J. Pharmacol. (1992) 105:73P.
  • TAYLOR SG, BUCKLE DR, SHAW DJ, WARD JS, ARCH JRS:An investigation of the selectivities of BRL 55834 and BRL 38227 as relaxants of guinea-pig tracheal spirals relative to portal vein. Br. J. Pharmacol. (1992) 105:242P.
  • TAYLOR SG, BUCKLE DR, FOSTER KA, SHAW DJ, WARD JS, ARCH JRS: Evidence that the novel airways selective benzopyranol, BRL 55834, is a potassium channel acti-vator. Br. J. Pharmacol. (1992) 105:247P.
  • BUCKLE DR, EGGLESTON DS, PINTO IL, SMITH DG, TED-DER JM: Synthesis of BRL 55834 - A Novel, Potent Airways-Selective Potassium Channel Activator. Bioorg. Med. Chem. Lett. (1992) 2:1161–1164.
  • BOWRING NE, ARCH JRS, BUCKLE DR, TAYLOR JF: Conv parison of the Airways Relaxant and Hypotensive Po-tencies of the Potassium Channel Activators BRL 55834 and Levcromakalim (BRL 38227) In Vivo in Guinea-Pigs and Rats. Br. J. Pharmacol. (1993) 109:1133-1139. In vivo evaluation of tracheal selectivity of BRL 55834.
  • MIURA M, BELVISI MG, WARD J K, TADJKARIMI S, YACOUBMH, BARNES PJ: Bronchodilating Effects of the Novel Potassium Channel Opener HOE 234 in Human Airways In Vitro. Br. J. Clin Pharmacol. (1993) 35:318.
  • ENGLERT HC, WIRTH K, GEHRING, D, FURST U, ALBUS U,SCHOLZ W, ROSENKRANZ B, SCHOLKENS BA: Airway Pharmacology of the Potassium Channel Opener HOE 234, in Guinea-Pigs: In Vitro and In Vivo Studies. Eur. Pharmacol (1992) 210:69.
  • KIDNEY JC, LarvALL, jo, LEI Y, CHUNG 1CF, BARNES PJ: A comparison of the inhaled IC+ channel openers BRL 38227 and HOE 234 against histamine-induced bron-choconstriction and airway microvascular leakage. Am. Rev Respir. Des. (1992) 145:A202.
  • KIDNEY JC, LEI Y, CHUNG 1CF, BARNES PJ: Inhaled K+ channel opener HOE 234 protects against non adrener-gic non cholinergic bronchoconstriction. Am. Rev Respir. Des. (1992) 145:A202.
  • KLAUS E, ENGLERT HC; LINZ W, BARTSCH C, SCHOLKENSBA: Effects of the potassium channel openers HOE 234 and lemakalim in rat aorta. Naunyn-Schmedeberg's Arch. Pharrn. (1992) 345 (Suppl 1):R71.
  • KOGA H, SATO H, ISHIZAWA T, KUROMARU K, NABATAH, IMAGAWA J, YOSHIDA S, SUGO I: /V,N-disubstituted benzopyran-4- (N'-cyano)carboxamidines, cromakallm analogs with selective activity for guinea-pig trachelais. Bioorg. Med. Chem. Lett. (1993) 3:1111–1114.
  • GIARDINO EC, KATZ LB, HAERTLEIN B, BARRETT JA, FALOTICO R: Vasodilating effects of the novel potassium channel activator RWJ 29009 In conscious dogs. EASES J. (1992) 6:2053.
  • STUMP GL, CHEUNG WC, SALATA B, DAMIAN() BP: Car-diac electrophysiologk effects of RWJ-29009, a new potassium channel activator. FASEBJ. (1992) 6:2052.
  • DAMIANO BP, STUMP GL, CHEUNG W, SALATA JJ: In vivocardiac electrophysiologic of RWJ 29009, a new potas-sium-channel activator, in comparison to cromakaiim and nicardipine. J. Cardiovasc. Pbarmacol. (1993) 22:143–152.
  • JACOBY HI, TOMKO, KA, STEFFLER C, LEE D KH: Vasore-laxant effect of the potassium channel activator, RWJ 29009, is tissue selective. Life Sci. (1993) 52:PL 233–238. Discusses vascular tissue selectivity.
  • SANFILIPPO PJ, McNALLY JJ, PRESS JB, FITZPATRICK LJ,URBANSKI MJ, KATZ LB, GIARDINO E, FALOTICO R, SALATA J, MOORE JB, MILLER W: Thiophene systems. 14. synthesis and antihypertensive activity of novel 7-(cy-clic amido)-6-hydroxythieno[3,2-b]pyrans and related compounds as new potassium channel activators. J. Med. Chem. (1992) 35:4425–4433.
  • HEDLUND H, MATTIASSON A, ADERSSON ICE: Effects ofpinacidil on detrusor instability in men with bladder outlet obstruction. J. Urn!. (1991) 146:1345–1347.
  • LAURENT F, MICHEL A, BONNET PA, CHAPAT JP, BOU-CARD M: Evaluation of the relaxant effects of SCA 40, a novel charybdotoxin-sensitive potassium channel opener, in guinea-pig isolated trachealis. Br. J. Pharma-col. (1993) 108:622-626. Potential therapeutic uses of BKCa openers.
  • MCMANUS OB, HARRIS GH, GIANGIACOMO KM, FEIGEN-BAUM P, REUBEN JP, ADDY ME, BURKA JF, KACZOROWSKI GJ, GARCIA ML: An activator of calcium-dependent po-tassium channels isolated from a medicinal herb. Bio-chemistry (1993) 32:6128–6133.
  • BLACKBURN TP; CHAN WN, EVANS JM; THOMPSON M, UPTON N: New benzoylamino benzopyrans as potential anticonvulsant agents. 7th RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK (1993): P8.
  • MANLEY P W, QUAST U, ANDRES H, BRAY K: Synthesis of and radioligand binding studies with a tritiated pinacidil analog: receptor interactions of structurally different classes of potassium channel openers and blockers. J. Med. Chem. (1993) 36:2004–2010.
  • ISHIZAWA T, KOGA H, OHTA M, SATO H, MAKINO T, KUROMARU K, TAKA N, TAKAHASHI T, SATO T, NABATA H: Structure-activity relationships of 6-substituted ben-zopyran-4-carbothioamide potassium channel open-ers. Bioorganic & Medicinal Chemistry Letters (1993) 3: 1659-1662.
  • KOGA ii, OFITA M, SATO H, ISHIZAWA T, NABATA Design of potent K+ channel openers by pharmaco-phore model Biomganic & Medicinal Chemistry Letters (1993) 3:625–631.
  • BUCKLE OR, EGGLESTON DS, HOUGE-FRYDRYCH CSV, PINTO IL, READSHAW SA, SMITH DG, WEBSTER RAB: Conformational and steric modifications of the pyran ring of the potassium channel activator cromakalirn. Chem. Soc. Perkin Trans. 1 (1991):2763–2771.
  • PIROTTE B, DUPONT L, DETULLIO P, MASEREEL B, SCHYNTS M, DELARGE J: Structural study of pinacidil, a potassium channel opener belonging to the chemical class of N-alkyl-N"-cyano-N'-pyridylguanidines. Hely. Cbim. Acta (1993) 76:1311–1318.
  • QUAST U: Do the K+ channel openers relax smooth muscle by opening K-1- channels? TiPS (1993) 14:332–337.
  • BEECH DJ, ZHANG H, NAKAO K, BOLTON TB: K channel activation by nucleotide diphospbates and its Inhibi-tion by glyburide in vascular smooth muscle cells. Br. J. Pbarmacol. (1993) 100:573–582.
  • BEECH DJ, ZHANG H, NAKAO K, BOLTON TB: Singlechannel and whole-cell K-currents evoked by levcro-makalim in smooth muscle cells from the rat portal vein. Br. J. Pharmacol. (1993) 100:583-590. Studies suggesting site of action of levcromakalim.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.